tbuckley/cabot-search huggingface dataset:
The “Next Big Thing” in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design—Between the Lines
Authors: Kai Ruggeri, Áine Maguire, Gordon Cook
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
Authors: Frederick L Altice, Lyuba Azbel, Jack Stone, Ellen Brooks-Pollock, Pavlo Smyrnov, Sergii Dvoriak, Faye S Taxman, Nabila El-Bassel, Natasha K Martin, Robert Booth, Heino Stöver, Kate Dolan, Peter Vickerman
Journal: The Lancet (2016)
Malignant Lymphoma
Authors: Alan C. Aisenberg
Journal: New England Journal of Medicine (1973)

Viral Causation of Animal LymphomaA REMARKABLY coherent view of the etiology of animal lymphoma and lymphoid leukemia has emerged in the decade since human lymphoma was last reviewed in the New England Journal of Medicine.1 Lymphomas and lymphoid leukemias are prominent disorders in most animal species subject to close medical scrutiny. Over the past 10 years evidence has accumulated that these neoplasms of lower forms are almost universally of viral causation. Thus, the evidence is conclusive that lymphoid leukemias and lymphomas of mice, rats, chickens and cats are caused by oncogenic viruses (usually RNA viruses with C-type morphology), and . . .
Childhood Trauma as a Neglected Factor in Psychotic Experiences and Cognitive Functioning
Authors: Marieke J. H. Begemann, Sophie M. Heringa, Iris E. C. Sommer
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Implant for Opioid Dependence
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis
Authors: Magda Lourda, Selma Olsson-Åkefeldt, Désirée Gavhed, Ulla Axdorph Nygell, Gösta Berlin, Evaldas Laurencikas, Tatiana von Bahr Greenwood, Mattias Svensson, Jan-Inge Henter
Journal: Blood (2016)
Do crocodiles and alligators hold the key to cancer treatment?
Authors: Ruqaiyyah Siddiqui, Salwa Mansoor, Naveed Ahmed Khan
Journal: BMJ (2016)

By 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths. Cancer is often linked to environmental pollutants, chemicals, infectious agents, genetics, hormones, and radiation.

From visits to crocodile sanctuaries, it is evident that crocodiles can live in unhygienic conditions; feed on rotten …
Amiodarone and Arrhythmias.
Authors: Walter Somerville
Journal: Annals of Internal Medicine (1983)

This book is an exception to the rule that communications designed to be spoken seldom make easy reading.The senior editor is known to share this view and his editorial discipline, passed on to his co-editors, is sensed in all the articles and particularly in the discussion which appears pruned of all the irritating circumlocutions of the spoken word.Amiodarone deserves good publicity and now that it is generally available in this country, its use calls for well-informed guidance.
PD-020 Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Authors: S. Faivre, J.-F. Blanc, P. Merle, A. Fasolo, A. Iacobellis, V. Grando, T. Decaens, J. Trojan, E. Villa, U. Stammberger, R. Bruns, E. Raymond
Journal: Annals of Oncology (2016)
P-003 Extended Mutational Profiling for Metastatic Colorectal Cancer (CRC): beyond RAS Molecular Spectrum of KRAS-NRAS-BRAF and PI3K in Cancer Colorectal
Authors: S. Otero, P. Saldias, M. Sanchez, M. Colica, G. Bramuglia, G. Jankilevich
Journal: Annals of Oncology (2016)
P0809 : 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study
Authors: J.-H. Kao, S.-H. Ahn, R.-N. Chien, S.-H. Jeong, C.-Y. Peng, Y.-S. Lim, J.C. Yang, H. Mo, L.-L. Han, D. Brainard, S.J. Knox, J.G. McHutchison, Y.-J. Lee, T.-T. Chang, S.-W. Paik, C.-J. Chu, W.-L. Chuang, K.-H. Han
Journal: Journal of Hepatology (2015)
European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
Authors: Francesco Bonella, Marlies Wijsenbeek, Maria Molina-Molina, Annette Duck, Rosalba Mele, Klaus Geissler, Wim Wuyts
Journal: European Respiratory Journal (2016)

We would like to acknowledge the comments of A. Bush and colleagues on the European idiopathic pulmonary fibrosis (IPF) Patient Charter and seize the opportunity to provide additional information on this important initiative. The European IPF Charter paved the way to improve care and raise visibility of the needs of patients affected by ILD <http://ow.ly/4nrVHV>
Correlation between PD-L1 expression and PD-1 immune checkpoint blockade: A retrospective analysis for advanced melanoma.
Authors: Jinhyun Cho, Soomin Ahn, Kwai Han Yoo, Haa-na Song, Ki Sun Jung, Kee-Taek Jang, Jeeyun Lee
Journal: Journal of Clinical Oncology (2016)

e21007 Background: Overexpression of PD-L1 is associated with better clinical responses to PD-1/PD-L1 blockade in melanoma, but the utility of PD-L1 immunostaining as a predictive biomarker for anti-PD-1 treatment remains unclear. Methods: We retrospectively assessed 18 patients with metastatic melanoma (10 acral, 8 mucosal primary) who had received anti-PD-1 treatment to evaluate the association between PD-L1 immunostaining status and the efficacy of anti-PD-1 treatment between January and December 2015 at single tertiary center in Korea. Immunohistochemical PD-L1 expression was evaluated with cutoff values of 1% or 5% of immune cells in a tissue section. The primary endpoint was progression free survival (PFS) and secondary endpoints were overall response rate (ORR), disease control rate (DCR), and Safety. Results: In the positive group with 1% cutoff, ORR was 20% (2/10) and DCR was 80%; for patients with negative immunostaining, ORR was 12.5% (1/8) and DCR of 37.5%, respectively. With 1% cutoff value, the median PFS was 6.2 months in positive group and 1.6 months in negative group (p = 0.137). In the positive group with 5% cutoff value, ORR was 33.3% (2/6) and DCR was 83.3%; for patients with negative immunostaining, ORR was 8.3% (1/12) and DCR was 50%. With 5% cutoff value, the median PFS was 6.8 months in positive group and 1.9 months in negative group (p= 0.149). One patient with positivity for anti-PD-L1 immunostaining ( ≥ 5%) and three patients with negativity for anti-PD-L1 immunostaining ( < 1%) continued anti-PD-1 treatment beyond RECIST-defined disease progression. These four patients experienced stable disease with immunotherapy for more than 5 months since the date of documented initial disease progression. Anti-PD-1 treatment was very well tolerated without serious adverse events of grade 3 or 4 in all patients. Conclusions: Within the limitation of a retrospective study, immunohistochemical PD-L1 expression was correlated with better clinical outcomes of anti-PD-1 treatment, but cannot be considered a definitive biomarker for the response to PD-1 checkpoint blockade.
APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume
Authors: Barry I. Freedman, Crystal A. Gadegbeku, R. Nick Bryan, Nicholette D. Palmer, Pamela J. Hicks, Lijun Ma, Michael V. Rocco, S. Carrie Smith, Jianzhao Xu, Christopher T. Whitlow, Benjamin C. Wagner, Carl D. Langefeld, Amret T. Hawfield, Jeffrey T. Bates, Alan J. Lerner, Dominic S. Raj, Mohammad S. Sadaghiani, Robert D. Toto, Jackson T. Wright, Donald W. Bowden, Jeff D. Williamson, Kaycee M. Sink, Joseph A. Maldjian, Nicholas M. Pajewski, Jasmin Divers
Journal: Kidney International (2016)
P-071 Clinical relevance of histologic subtype in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy followed by surgery
Authors: M. Saigí, M. Oliva, L. Aliste, G. Hormigo, M. Calvo, Ò. Serra, L. Farran, M. Miró, M. Boladeras Ana, J. Robles, M. Botargues Josep, E. de Lama, J. Pérez Martín Francisco, J. Paúles Maria, G. Creus, M. Galán
Journal: Annals of Oncology (2016)
Evaluation of breast cancer incidence in Lynch syndrome patients by MMR gene.
Authors: Jamie Willmott, Adam Johnson, Kelsey Moyes, Brent Evans, Christopher Arnell, Michelle Landon
Journal: Journal of Clinical Oncology (2014)

1541 Background: The current literature is divided as to whether or not breast cancer (BC) is a feature of Lynch syndrome (LS). The aim of this analysis was to investigate the prevalence of BC in patients with mutations in the individual mismatch repair (MMR) genes that cause LS. Methods: A retrospective review of patients’ personal and family history of cancer was performed on patients with LS-causing mutations. All patients that underwent full sequencing and/or large rearrangement testing for mutations in MLH1, MSH2, MSH6, PMS2 or EPCAM at Myriad Genetic Laboratories between September 2006 and October 2013 were included. Patients were excluded if they only had single site testing for a known LS mutation or if they were known to have a mutation in BRCA1 or BRCA2. A Pearson chi-square test was performed to determine if the prevalence of breast cancer was significantly different among individual MMR genes. Exact confidence limits for binomial proportions were then computed. Results: A total of 5,638 patients with a LS-causing gene mutation were identified and the proportion of patients with BC was calculated for each gene. A chi-square test shows that at least one of these proportions is statistically significantly different from the others (p=0.007). The percentages (with 95% confidence intervals (CI)) of patients with BC by gene are 5.9% (4.6% - 7.5%) for MSH6, 4.0% (2.2 % - 6.8%) for PMS2, 3.7% (3.0% - 4.5%) for MSH2, 3.2% (2.5% - 4.1%) for MLH1, and 1.8% (0.05% - 9.7%) for EPCAM. Conclusions: The confidence interval for the proportion of MSH6 carriers with BC does not overlap with those for MLH1 and MSH2. Our results suggest that a personal history of BC is more prevalent in MSH6 mutation carriers than in LS patients with mutations in other MMR genes. This may explain some of the confusion surrounding the inclusion of BC as a Lynch syndrome-associated cancer. Rather than taking an approach of accepting or rejecting that BC is associated with LS as a whole, it may be more appropriate to define BC risks by specific MMR gene or a broader panel of genes. MLH1 N=1857 MSH2 n=2372 MSH6 n=1032 PMS2 n=322 EPCAM n=55 Personal history of breast cancer - n (%) [95% CI] 60 (3.2%) [2.5% - 4.1%] 87 (3.7%) [3.0% - 4.5%] 61 (5.9%) [4.6% - 7.5%] 13 (4.0%) [2.2% - 6.8%] 1 (1.8%) [0.05% - 9.7%]
Intellectual and neuropsychological functions in young men with heavy and long-term patterns of drug abuse
Authors: P Bruhn, N Maage
Journal: American Journal of Psychiatry (1975)

The authors attempted to determine the long-term effects of heavy drug abuse in 87 male prisoners. The sample was divided into the following groups: 1) nondrug users; 2) users of cannabis and hallucinogens; 3) users of cannabis, hallucinogens, and amphetamines; and 4) users of cannabis, hallucinogens, amphetamines, and opiates. Intellectual and neuropsychological tests sensitive to brain dysfunction revealed no intergroup differences. This finding casts some doubt on other reports suggesting that long-term drug abuse results in neuropsychological disorders. However, the authors caution that one should not conclude that no organic changes occurred in their sample.
Reply
Authors: Lily Dara, Neil Kaplowitz
Journal: Hepatology (2015)

Potential conflict of interest: Nothing to report. We thank Yang et al. for their communication regarding our recently published work.1 The authors raise the important issue of primary mouse hepatocyte (PMH) dedifferentiation in culture. We considered this and looked for RIPK3 in "freshly isolated PMH" multiple times in phosphate‐buffered saline–treated mice and mice treated with acetaminophen (APAP) for 3 hours. After collagenase perfusion of the liver and allowing for PMH to precipitate in the bottom of Hank's balanced salt solution, an additional short Percoll spin was done to further separate PMH from nonparenchymal cells. PMHs were then washed and immediately boiled in Laemmeli sample buffer for western blotting. We also conducted experiments in which we plated PMH and treated with control media or APAP 5 and 10 mM for up to 24 hours and collected samples at 3‐hour intervals. These experiments were repeated numerous times, using different mice and on different dates. We were unable to detect RIPK3 at baseline or after APAP in PMH using the monoclonal antibody in any of these conditions. Regarding the Proscience antibody, as you can see in the supplementary materials there is a nonspecific band around the molecular weight of 55KD, which is also present in RIPK3–/– liver. The polyclonal commercially available antisera all had varying degrees of nonspecific bands when blotting liver tissue in particular. We ran the exact same samples and blotted with the monoclonal antibody by Genentech and, as you can see in the figures, could not detect RIPK3 and the band was much cleaner and more specific. It is important to note that in the Ramachandran article, western blotting using the Proscience antibody was only done on whole‐liver lysates and not isolated primary hepatocytes. However, they did use a knockout as negative control (unclear if knockout sample was liver homogenate). Regardless, it is clear that the monoclonal antibody is very specific and superior for detection of RIPK3 protein using western blotting. Yang et al. suggest that the role of the innate immune system is not excluded, given that the antisense‐MOE, which concentrates in the liver, may have also knocked down RIPK1 in nonparenchymal cells such as Kupffer cells (KCs) and natural killer (NK) cells. Though the role of KCs, neutrophils, NK, and NKT cells has been examined in murine APAP toxicity, there is no conclusive evidence of their participation in the injury phase.2 However, we acknowledge that is a possibility, which needs to be explored further and thank them for their comments and interest in our work.
Physical Activity and Cancer Outcomes: A Precision Medicine Approach
Authors: Christine M. Friedenreich, Heather K. Neilson, Megan S. Farris, Kerry S. Courneya
Journal: Clinical Cancer Research (2016)

There is increasing interest in applying a precision medicine approach to understanding exercise as a potential treatment for cancer. We aimed to inform this new approach by appraising epidemiologic literature relating postdiagnosis physical activity to cancer outcomes overall and by molecular/genetic subgroups. Across 26 studies of breast, colorectal, and prostate cancer patients, a 37% reduction was seen in risk of cancer-specific mortality, comparing the most versus the least active patients (pooled relative risk = 0.63; 95% confidence interval: 0.54-0.73). Risks of recurrence or recurrence/cancer-specific death (combined outcome) were also reduced based on fewer studies. We identified ten studies of associations between physical activity and cancer outcomes by molecular or genetic markers. Two studies showed statistically significant risk reductions in breast cancer mortality/recurrence for the most (versus least) physically active estrogen receptor-positive/progesterone receptor-positive (ER+/PR+) patients, while others showed risk reductions among ER-PR- and triple-negative patients. In colorectal cancer, four studies showed statistically significant risk reductions in cancer-specific mortality for patients with high (versus low) physical activity and P21 expression, P27 expression, nuclear CTNNB1-, PTGS2 (COX-2)+, or IRS1 low/negative status. One prostate cancer study showed effect modification by Gleason score. As a means to enhance this evidence, future observational studies are needed that will measure physical activity objectively before and after diagnosis, use standardized definitions for outcomes, control for competing risks, assess nonlinear dose-response relations, and consider reverse causality. Ultimately, randomized controlled trials with clinical cancer outcomes and a correlative component will provide the best evidence of causality, relating exercise to cancer outcomes, overall and for molecular and genetic subgroups. Clin Cancer Res; 22(19); 4766-75. ©2016 AACR.
Dietary Intake Among US Adults, 1999-2012
Authors: Colin D. Rehm, José L. Peñalvo, Ashkan Afshin, Dariush Mozaffarian
Journal: JAMA (2016)

Most studies of US dietary trends have evaluated major macronutrients or only a few dietary factors. Understanding trends in summary measures of diet quality for multiple individual foods and nutrients, and the corresponding disparities among population subgroups, is crucial to identify challenges and opportunities to improve dietary intake for all US adults.
THROMBOCYTOPENIA IN ROCKY MOUNTAIN SPOTTED FEVER
Authors: H W Garbee, W M Kelsey
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US Dietary Recommendations—Reply
Authors: Karen B. DeSalvo
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Full-Intensity Transplantation and Short Telomeres Increase The Risk Of Cognitive Impairment After Allogeneic Hematopoietic Cell Transplantation (HCT) – Results Of a Prospective Longitudinal Study
Authors: Alysia Bosworth, Yanjun Chen, Sunita K. Patel, Emily Blum, Can-Lan Sun, Yan Ding, Jennifer Noe, Liton Francisco, Marcia Grant, Stephen J. Forman, F. Lennie Wong, Smita Bhatia
Journal: Blood (2013)